Anthropic's Claude Science is a 'front door' for drug discovery, executive says

What Claude Science does

Eric Kauderer-Abrams, Anthropic's head of life sciences, told pharmaphorum's Deep Dive that Claude Science is the "front door" for scientists. Instead of switching between a document, code, a web browser and a terminal to run specialised tools, he said, users go to Claude Science and let it coordinate the other tools and product surfaces.

He said the product is complementary to NVIDIA's BioNemo Toolkit, which provides access to specialised machine learning models for specific tasks. Anthropic says Claude is used in drug discovery to automate workloads and analyse large datasets. That description does not claim the model designs molecules or predicts clinical outcomes.

Anthropic announced Claude Science in July 2026. Pharmaceutical Technology reported that Anthropic said the tool was designed to integrate fragmented tools and databases across the drug discovery workflow.

Pharmaphorum reported that Anthropic is making Claude Science available to researchers for free or at a discount to enable fast exploration of the tool's potential. Kauderer-Abrams said the priority is having scientists push the limits of what its models and products can do.

The model underneath

Kauderer-Abrams said life sciences work, including biology and life-sciences-related chemistry, uses the latest Opus model. Physics, maths and materials science use Fable. He said Fable models have biosafety classifiers because their capabilities pose increased risk, and Anthropic aims to scale up its trusted access program for Claude Opus 5 for biology and chemistry.

Oliver Vince, co-founder of Basecamp Research, told pharmaphorum that Claude lets a team try ten ideas at once rather than one at a time, then automate the best one. He described the effect as "like having a team of PhD students at your hands".

Six research partners, not all named

Anthropic says its scientists have formed research partnerships with six organisations developing new medicines. Anthropic has not named all six. That gap matters for buyers trying to judge the product's real-world use.

Anthropic, PBC filed a Form S-1 with the SEC for a proposed IPO of Class A common stock. It intends to list on Nasdaq under the ticker "ANT". The filing disclosed no share count, offering price, amount raised, valuation or IPO date. That leaves investors with a story and no price tag. As a public benefit corporation, the company's board can weigh a stated public mission alongside shareholder returns.

What happens next

The S-1 has not become effective. No IPO date, price or share count has been set. Anthropic is currently offering Claude Science free or at a discount; it has not announced commercial pricing.

For buyers, the open question is what the front door costs once the discount ends, and whether access to data and lab integration matter more than model benchmarks.